

Inflammation Bowel Diseases and Tuberculosis Infection

Elanaz Alizade*, Yasir Furkan Çağın and Ali Alizade

Department of Hematology, Inonu University Turgut Ozal Medical Center, Turkey

Keywords: Inflammatory Bowel Diseases, Intestinal tuberculosis

Introduction

Inflammatory Bowel Diseases (IBD), including Crohn's disease (CD) and ulcerative colitis, are chronic inflammatory conditions due to a variable breakdown reaction. Ulcerative colitis (UC) is a chronic inflammatory disease characterized by mucosal inflammation that begins distal to the rectum and continues for a variable distance proximally, there is often a sharp boundary between inflamed and non-inflamed mucosa. Typically, patients with UC experience periods of relapse and remission [1-2] Crohn's disease is a complex, chronic inflammatory gastrointestinal condition that varies in age of onset, disease location, and behavior.² Intermittent attacks of the disease, ileal involvement and granulomatous inflammation are more suggestive of Crohn's disease, as is the tendency to inflammation in the proximal colon. In 5–15% of IBD patients, endoscopic and histological assessments cannot distinguish between Crohn's colitis and UC, and these patients are labelled as IBD-unclassified (IBD-U).

Differentiating between intestinal tuberculosis (ITB) and Crohn's disease may be challenging in those who have lived in endemic areas as clinical features may be similar. Features suggestive of a diagnosis of intestinal TB include night sweats, concomitant pulmonary tuberculosis, positive tuberculin skin test, antibodies to TB, abdominal lymphadenopathy, ascites AND transverse ulcers. The frequency of extra-pulmonary tuberculosis is firstly the lymph node, then the genitourinary system, and the third intestinal system.

The difference between IBD and ITB needs to be understood in terms of treatment. If the patient is initiated with IBD treatment instead of ITB, it may cause a worsening of the patient's clinic conditions due to immune suppressive treatment, such as corticosteroids and anti-tumor necrosis factors.

Case Report

1. In 2010, a 31-year-old male patient applied to the polyclinic with bloody diarrhea and weight loss. His complaints first started at the age of 26.

The patient's first colonoscopy was considered in favor of ulcerative colitis.

Mesalamine and enema were started and he was called for control after 15 days.

The patient, who came for control 15 days later, stated that his diarrhea continued. The patient's treatment dosage was increased and he was called for a re-control.

Pathology report received from the patient, chronic (active) diffuse colitis, Low grade dysplasia concluded.

The patient who came to show the biopsy results and re-control, stated that his complaints had not decreased. Corticosteroid treatment was started.

After corticosteroid treatment started, the patient's complaints

decreased. He had regular colonoscopy and biopsy taken during this process.

He received the same treatment for 10 years. Even if it was recommended to discontinue corticosteroid, continued with his own will.

After reducing the corticosteroid dosage, the patient applied with the complaint of defecation 15-18 times a day and lost 20kg in 4 months.

The patient was started on Infliximab, Azathioprine along with mesalamin. He received 4 doses of infliximab His diarrhea continued 7-8 times a day.

2. In 2021, the IGBT test taken from the patient was positive. His tuberculosis treatment has started. Biopsy result taken during colonoscopy diffuse active colitis concluded.

3. In 2023, the patient's colonoscopy: linear large ulcer and fistula orifice were observed. lead pipe deformity developed. Ileocecal valv was observed to be ulcerated and deformed (crohn).

After his colonoscopy in 2023, he was admitted to the hospital due to fever. He had left inguinal pain for about 2 months. Thrombosis was not detected as a doppler result. MRI was performed on the patient and it resulted in iliopsoas abscess.

The abscess was drained by the general surgery and the result of the abscess culture was explained as tuberculosis. Anti-tuberculosis treatment has started.

The patient was transferred to intensive care due to tachycardia and low saturation.

The patient, who was followed in the ICU, was suddenly intubated due to cardiopulmonary arrest and was returned after 35 minutes of CPR. He was followed as intubated.

After 7 days, massive bloody diarrhea started. PPI infusion and somatostatin infusion was started to the patient. After 13 days, the patient died in the ICU, despite of all the interventions.

Discussion

In 2010, 31-year-old male patient applied to the polyclinic with bloody diarrhea and weight loss. His complaints first started when

*Corresponding author: Dr. Elanaz Alizade, Department of Hematology, Inonu University Turgut Ozal Medical Center, Turkey, E-mail: hmhmemar@gmail.com

Received: 1-Mar-2024, Manuscript No: science-24-127703, Editor assigned: 3-Mar-2024, Pre QC No: science-24-127703(PQ), Reviewed: 17-Mar-2024, QC No: science-24-127703, Revised: 19-Mar-2024, Manuscript No: science-24-127703(R), Published: 25-Mar-2024, DOI: 10.4172/science.1000213

Citation: Alizade E (2024) Inflammation Bowel Diseases and Tuberculosis Infection. Arch Sci 8: 213.

Copyright: © 2024 Alizade E. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.

he was 26 years old. The patient's first colonoscopy was considered in favor of ulcerative colitis.

LAB: ANTI HBS (MIKRO) Negatif IU/ML, ANTI HIV(MACRO) Negatif, ANTI HCV(MACRO) Negatif, ANTI HBC TOTAL(MACRO) Negatif, HBSAG(MACRO) Negatif,

Total Bilirubin 0, 2 mg/dL

Direct Bilirubin 0, 2 mg/dL

AST 15 U/L

ALT 19 U/L

ALP 62 U/L

GGT 30 U/L

LDH 146 U/L

HGB 6, 2 g/dL

HCT 21, 2 %

PLT 713 10³/ML

Sedimentation 120 mm/H

PTZ - INR 1, 2

APTT 26, 8 sn

CMV PCR NEGATIF

İGST NEGATIF

The patient was on mesalamine and enema + corticosteroid started. After 10 years of treatment the patient was started on Infliximab, Azathioprine along with Mesalamin. He received 4 doses of infliximab.

In 2021, the IGST test taken from the patient was positive. His tuberculosis treatment has started.

LAB: CRP 2, 25 mg/Dl

Albumin 3, 6 g/dL

Total Bilirubin 0,3 mg/dL

Direct Bilirubin 0,07

AST 34 IU/L

ALT 35 IU/L

ALP 184 IU/L

GGT 187 IU/L

LDH 163

HGB 12 g/dL

HCT 41, 1 %

CMV PCR NEGATIF

IN 2022, the IGST test taken from the patient was negatif.

LAB: CRP 3, 33 mg/dL

Albumin 3, 8 g/dL

Total Bilirubin 0, 3 mg/dL

Direct Bilirubin 0, 04 mg/dL

AST 22 U/L

ALT 20 U/L

ALP 72 U/L

GGT 24 IU/L

LDH 136 U/L

HGB 11, 6 g/dL

HCT 38 %

Sedimentation 26 mm/H

In 2023, he had left inguinal pain for about 2 months. Thrombosis was not detected as a doppler result. MRI was performed on the patient and it resulted in iliopsoas abscess . The abscess was drained by the general surgery and the result of the abscess culture was explained as tuberculosis. Anti-tuberculosis treatment has started.

LAB

Albumin 2, 7 g/dL

Total Bilirubin 0, 31 mg/dL

Direct Bilirubin 0, 07 mg/dL

AST 18 U/L

ALT 14 U/L

ALP 76 U/L

GGT 78 IU/L

LDH 212 U/L

AMİLAZ 90 U/L

LİPAZ 41, 9 U/L

HGB 7.60 g/dL

HCT 22.90 %

PTZ - INR 1, 29

PTZ - sn 15, 3 sn

CRP 11, 5

TBC PCR NEGATIF

CMV PCR NEGATIF

Clostridium difficile NEGATIF

The cause of the patient's first cardiopulmonary arrest was not understood.

Very resistant Klebsiella Pneumoniae was grown in the blood culture of the patient who continued to be Icutated.

The patient is considered to exitus due to sepsis.

Conclusion

Due to the similarities between CD and gastrointestinal TB (GITB) It can be difficult to distinguish between the two diseases:

- There are significant similarities in the clinical, radiological, endoscopic, surgical, and histological features of CD and gitB (which typically occurs in the ileocecal region).

- CD and giTB are both granulomatous conditions that can involve any part of the gastrointestinal tract;

- There is no simple test that can be used to reliably distinguish CD from giTB.

Patients with IBD frequently develop serious infections resulting from the disease itself or its treatment [3]. Although some patients may be asymptomatic, common symptoms of Gastrointestinal (GI) tuberculosis (TB) are fever, anorexia, weight loss, nausea/vomiting, abdominal pain, diarrhea, and sometimes constipation. Hematemesis and melena are uncommon. On physical examination, signs such as abdominal distension, ascites, hepatomegaly, splenomegaly, rectal bleeding may be detected depending on the involved area of GI tract [4]. 10% of people infected with tuberculosis develop active tuberculosis, and the remaining 90% have latent tuberculosis infection (LTBI); this infection does not require treatment because tuberculosis bacteria are present in the body but their activity is suppressed and there are no symptoms or contagiousness [5]. Latent tuberculosis (TB) infections (LTBI) pose clinical challenges for the diagnosis and treatment of inflammatory bowel disease (IBD) especially in TB-endemic areas. While steroids and biologics are becoming increasingly useful in

treating patients with moderate to severe IBD, the risk of developing reactivation or TB increases due to their strong immunosuppressive effects [5]. Tumor necrosis factor- α inhibition can lead to activation of latent TB infection, and most cases present as more severe forms of disseminated TB [5].

References

1. Ranga RS, Sowmyalakshmi S, Burikhanov R, Akbarsha MA, Chendil D, et al. (2005) A herbal medicine for the treatment of lung cancer. *Mol Cell Biochem* 280: 125-133.
2. Leopoldina M, Marino T, Russo N, Toscano M (2004) Antioxidant properties of phenolic compounds: H- atom versus electron transfer mechanism. *J Phys Chem A* 108: 4916-4922.
3. Mohammad P, Nosratollah Z, Mohammad R, Abbas A Javad R, et al. (2010) The inhibitory effect of *Curcuma longa* extract on telomerase activity in A549 lung cancer cell line. *Afr J Biotechnol* 9: 912-919.
4. Amarowicz R, Pegg RB, Rahimi-Moghaddam P, Barl B, Well JA, et al. (2004) Free radical scavenging capacity and antioxidant activity of selected plant species from the Canadian prairies. *Food Chemistry* 84: 551-562.
5. Nisar T, Iqbal M, Raza A, Safdar M, Iftikhar F, et al. (2015) Estimation of Total Phenolics and Free Radical Scavenging of Turmeric (*Curcuma longa*). *American-Eurasian J Agric & Environ Sci* 115:1272-1277.